Eribulin Advanz Pharma

Eribulin Mesylate is a chemotherapy medication used to treat certain types of cancer. This intravenous medication is manufactured by Advanz Pharma Limited and is available in the EU.

Eribulin Mesylate is primarily used in the treatment of advanced breast cancer and liposarcoma. It works by slowing or stopping the growth of cancer cells. Patients often wonder, 'What is Eribulin Mesylate used for?' This medication is typically prescribed for specific types of cancer that have spread or returned after other treatments.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may also experience fever, constipation, or peripheral neuropathy. These effects can vary from person to person and may not affect everyone who takes the medication.

Eribulin Mesylate should be handled with care and administered by a healthcare professional. It is important to follow the prescribed dosage and schedule. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

Eribulin Mesylate may interact with other medications, including those that affect the liver or bone marrow. It is important to discuss all current medications with a healthcare provider before starting Eribulin Mesylate. Alcohol and certain supplements may also interact with this medication.